Search - tctmd.com

Displaying 961 - 980 of 1334

Sort: Relevancy | Date

News Conference News TCT 2012

ADAPT-DES: Poor Clopidogrel Response Not Predictive of 1-Year Mortality

October 25, 2012

Presentation TCT 2012

ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Presenter: Gregg Stone

October 25, 2012

News Industry News

8500+ Patient Trial Validates Association between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012

October 25, 2012

Presentation TCT 2012

Clopidogrel Is Still the Choice for Most!

Presenter: Shamir Mehta

October 24, 2012

News Conference News TCT 2012

Wednesday, TCT 2012 Dailies

October 24, 2012

Presentation TCT 2012

TRILOGY ACS Angiographic Cohort: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in Patients with Non-ST-Segment Elevation ACS Who Are Medically Managed After...

Presenter: Stephen Wiviott

October 24, 2012

News Conference News TCT 2012

Tailored Clopidogrel Therapy Bests Prasugrel at Control of Platelet Reactivity in ACS

October 24, 2012

News Industry News

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

October 24, 2012

News Conference News TCT 2012

Presentations Examine Multiple Facets of Antiplatelet Agents

October 24, 2012

Presentation TCT 2012

TCT-54. The Influence of Smoking Status on the Pharmacodynamics of Prasugrel and Clopidogrel: The PARADOX Study

Presenter: Paul Gurbel

October 23, 2012

Presentation TCT 2012

TCT-51. Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-eluting Stents: Insight from the Florence Left Main-PCI...

Presenter: Renato Valenti

October 23, 2012

Presentation TCT 2012

TCT-49. A Comparison of 5 mg Prasugrel with 75 mg Clopidogrel in Very Elderly Coronary Artery Disease Patients: Pharmacodynamics and Rates of High on-Treatment Reactivity

Presenter: Joseph Jakubowski

October 23, 2012

Presentation TCT 2012

TCT-55. Major Adverse Cardiac Events Associated with Discontinuation of Clopidogrel Treatment Within the First Year After Coronary Stent Implantation in Western Denmark

Presenter: Michael Maeng

October 23, 2012

News Conference News TCT 2012

PARADOX: Smoking Enhances Effect of Clopidogrel, Prasugrel Unaffected by Smoking Status

October 23, 2012

News Industry News

New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient® (Prasugrel) or Plavix® (Clopidogrel) Pre

October 23, 2012

News Industry News

Boston Scientific Demonstrates Ongoing Structural Heart Advances at Transcatheter Cardiovascular Therapeutics 2012 in Miami

October 23, 2012

Presentation TCT 2012

PARADOX: A Prospective, Randomized Trial of Clopidogrel and Prasugrel in Smokers and Non-Smokers

Presenter: Paul Gurbel

October 22, 2012

Presentation TCT 2012

A Prospective, Randomized Trial of Tailored Clopidogrel Therapy vs. Prasugrel in Patients with High On-Treatment Platelet Reactivity

Presenter: Laurent Bonello

October 22, 2012

News Daily News

La Bivalirudina Reduce las Hemorragias en Pacientes NSTEMI sometidos a PCI

Jason Kahn

October 19, 2012

News Daily News

Bivalirudin Lowers Bleeding in NSTEMI Patients Undergoing PCI

Jason Kahn

October 19, 2012

Advertisement

ADAPT-DES: Poor Clopidogrel Response Not Predictive of 1-Year Mortality

ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

8500+ Patient Trial Validates Association between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012

Clopidogrel Is Still the Choice for Most!

Wednesday, TCT 2012 Dailies

TRILOGY ACS Angiographic Cohort: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in Patients with Non-ST-Segment Elevation ACS Who Are Medically Managed After...

Tailored Clopidogrel Therapy Bests Prasugrel at Control of Platelet Reactivity in ACS

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

Presentations Examine Multiple Facets of Antiplatelet Agents

TCT-54. The Influence of Smoking Status on the Pharmacodynamics of Prasugrel and Clopidogrel: The PARADOX Study

TCT-51. Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-eluting Stents: Insight from the Florence Left Main-PCI...

TCT-49. A Comparison of 5 mg Prasugrel with 75 mg Clopidogrel in Very Elderly Coronary Artery Disease Patients: Pharmacodynamics and Rates of High on-Treatment Reactivity

TCT-55. Major Adverse Cardiac Events Associated with Discontinuation of Clopidogrel Treatment Within the First Year After Coronary Stent Implantation in Western Denmark

PARADOX: Smoking Enhances Effect of Clopidogrel, Prasugrel Unaffected by Smoking Status

New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient® (Prasugrel) or Plavix® (Clopidogrel) Pre

Boston Scientific Demonstrates Ongoing Structural Heart Advances at Transcatheter Cardiovascular Therapeutics 2012 in Miami

PARADOX: A Prospective, Randomized Trial of Clopidogrel and Prasugrel in Smokers and Non-Smokers

A Prospective, Randomized Trial of Tailored Clopidogrel Therapy vs. Prasugrel in Patients with High On-Treatment Platelet Reactivity

La Bivalirudina Reduce las Hemorragias en Pacientes NSTEMI sometidos a PCI

Bivalirudin Lowers Bleeding in NSTEMI Patients Undergoing PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content